Long-term Survival of a Kidney Transplant Patient with Advanced Renal Cancer After Combination Therapy: a Case Report and Literature Review

Overview

Journal J Int Med Res

Publisher Sage Publications

Specialty General Medicine

Date 2024 Dec 24

PMID 39719073

Authors

Chao Peng

Weihao Wang

Jiajun Chen

Shouhua Pan

Gang Xu

Mengyao Li

Lulu Zhang

Yulei Li

Keyuan Zhao

Jing Jin

Affiliations

Soon will be listed here.

Abstract

renal transplant carcinoma, especially in the context of bilateral renal carcinoma, is rare and often presents as small, low-grade papillary renal cell carcinoma (RCC). There is currently no consensus or effective treatment for advanced metastatic RCC after kidney transplantation. A 40-year-old man developed renal transplant carcinoma with venous thrombus and lung metastases 13 years after transplantation. The patient underwent cytoreductive nephrectomy followed by sequential treatment with tyrosine kinase inhibitors (TKI) and anti-PD-1 monoclonal antibodies. After 2 years, the patient showed excellent graft function with no evidence of cancer progression. Despite subsequent graft failure, the disease remained controlled for more than 2 years and the patient survived for more than 3 years, which was significantly longer than the typical survival of 10 to 20 months in patients with advanced kidney cancer. The results suggest that combining cytoreductive nephrectomy with TKI and anti-PD-1 therapy may significantly prolong survival in patients with renal allograft carcinoma.

References

Lai H, Lin J, Hwang T, Liu Y, Yang A, Wu C . Programmed Cell Death 1 (PD-1) Inhibitors in Renal Transplant Patients with Advanced Cancer: A Double-Edged Sword?. Int J Mol Sci. 2019; 20(9). PMC: 6540260. DOI: 10.3390/ijms20092194. View

Ianhez L, Lucon M, Nahas W, Sabbaga E, Saldanha L, Lucon A . Renal cell carcinoma in renal transplant patients. Urology. 2007; 69(3):462-4. DOI: 10.1016/j.urology.2006.11.007. View

Tsaur I, Obermuller N, Jonas D, Blaheta R, Juengel E, Scheuermann E . De novo renal cell carcinoma of native and graft kidneys in renal transplant recipients. BJU Int. 2010; 108(2):229-34. DOI: 10.1111/j.1464-410X.2010.09856.x. View

Klatte T, Marberger M . Renal cell carcinoma of native kidneys in renal transplant patients. Curr Opin Urol. 2011; 21(5):376-9. DOI: 10.1097/MOU.0b013e32834962bf. View

Neuzillet Y, Lay F, Luccioni A, Daniel L, Berland Y, Coulange C . De novo renal cell carcinoma of native kidney in renal transplant recipients. Cancer. 2004; 103(2):251-7. DOI: 10.1002/cncr.20745. View

Laru L, Ronkainen H, Ohtonen P, Vaarala M . Nephrectomy improves the survival of metastatic renal cell cancer patients with moderate to good performance status-results from a Finnish nation-wide population-based study from 2005 to 2010. World J Surg Oncol. 2021; 19(1):190. PMC: 8240260. DOI: 10.1186/s12957-021-02308-0. View

Patel H, Karam J, Allaf M . Surgical Management of Advanced Kidney Cancer: The Role of Cytoreductive Nephrectomy and Lymphadenectomy. J Clin Oncol. 2018; :JCO2018790246. DOI: 10.1200/JCO.2018.79.0246. View

Kwatra V, Karanth N, Priyadarshana K, Charakidis M . Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report. J Med Case Rep. 2017; 11(1):73. PMC: 5357565. DOI: 10.1186/s13256-017-1229-z. View

Kalble T, Lucan M, Nicita G, Sells R, Burgos Revilla F, Wiesel M . EAU guidelines on renal transplantation. Eur Urol. 2005; 47(2):156-66. DOI: 10.1016/j.eururo.2004.02.009. View

10.

Au E, Wong G, Chapman J . Cancer in kidney transplant recipients. Nat Rev Nephrol. 2018; 14(8):508-520. DOI: 10.1038/s41581-018-0022-6. View

11.

Frasca G, Sandrini S, Cosmai L, Porta C, Asch W, Santoni M . Renal cancer in kidney transplanted patients. J Nephrol. 2015; 28(6):659-68. DOI: 10.1007/s40620-015-0219-8. View

12.

Mathieu R, Pignot G, Ingles A, Crepel M, Bigot P, Bernhard J . Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features. Urol Oncol. 2015; 33(8):339.e9-15. DOI: 10.1016/j.urolonc.2015.05.014. View

13.

Tollefson M, Krambeck A, Leibovich B, Blute M, Chow G . Surgical treatment of renal cell carcinoma in the immunocompromised transplant patient. Urology. 2009; 75(6):1373-7. DOI: 10.1016/j.urology.2009.06.085. View

14.

Motzer R, Russo P . Cytoreductive Nephrectomy - Patient Selection Is Key. N Engl J Med. 2018; 379(5):481-482. DOI: 10.1056/NEJMe1806331. View

15.

Krisl J, Doan V . Chemotherapy and Transplantation: The Role of Immunosuppression in Malignancy and a Review of Antineoplastic Agents in Solid Organ Transplant Recipients. Am J Transplant. 2017; 17(8):1974-1991. DOI: 10.1111/ajt.14238. View

16.

Farrugia D, Mahboob S, Cheshire J, Begaj I, Khosla S, Ray D . Malignancy-related mortality following kidney transplantation is common. Kidney Int. 2013; 85(6):1395-403. DOI: 10.1038/ki.2013.458. View

17.

Swords D, Al-Geizawi S, Farney A, Rogers J, Burkart J, Assimos D . Treatment options for renal cell carcinoma in renal allografts: a case series from a single institution. Clin Transplant. 2013; 27(2):E199-205. DOI: 10.1111/ctr.12088. View

18.

Mejean A, Ravaud A, Thezenas S, Colas S, Beauval J, Bensalah K . Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. N Engl J Med. 2018; 379(5):417-427. DOI: 10.1056/NEJMoa1803675. View

19.

Bhindi B, Abel E, Albiges L, Bensalah K, Boorjian S, Daneshmand S . Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol. 2018; 75(1):111-128. DOI: 10.1016/j.eururo.2018.09.016. View

20.

Spain L, Higgins R, Gopalakrishnan K, Turajlic S, Gore M, Larkin J . Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. Ann Oncol. 2016; 27(6):1135-1137. DOI: 10.1093/annonc/mdw130. View